PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System

NATICK, Massachusetts and ATLANTA, Georgia, March 16, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from its PERSEUS clinical program that demonstrated positive
safety and efficacy outcomes in workhorse lesions for the platinum chromium
TAXUS(R) Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS(R)
Express2(TM) Paclitaxel-Eluting Stent System. The results also reported a
similar safety profile and statistically superior efficacy outcomes in small
vessels for the TAXUS Element Stent compared to a historical control group of
patients receiving the Express(R) bare-metal stent.

Analysis of the data was presented at the American College of
Cardiology Annual Scientific Sessions during a late-breaking trial session by
Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and
Vascular Center and The Lindner Research Center in Cincinnati and the
Principal Investigator for the PERSEUS clinical program.

"We are very encouraged by the one-year data demonstrating
positive safety and efficacy outcomes for the TAXUS Element Stent and its
innovative platinum chromium alloy," said Dr. Kereiakes. "In my experience,
the TAXUS Element Stent offers increased flexibility, visibility and
deliverability compared with currently available products. The PERSEUS data
confirm that the proven TAXUS drug and polymer combination has been
successfully transferred to the Element platform with excellent performance
and comparable safety."

The TAXUS Element Stent is designed specifically for coronary
stenting. The novel stent architecture and proprietary platinum chromium
alloy combine to offer greater radial strength and flexibility. The stent
architecture helps create consistent lesion coverage and drug distribution
while improving deliverability, which is enhanced by an advanced catheter
delivery system. The higher density alloy provides superior visibility and
reduced recoil while permitting thinner struts compared to prior-generation
stents[1].

"Boston Scientific continues to build on its legacy of
drug-eluting stent leadership through the development of our third-generation
TAXUS Element Stent System," said Hank Kucheman, Executive Vice President and
Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "In
addition, we remain the only company to offer customers a choice of two
drugs."

The PERSEUS clinical program compares the TAXUS Element Stent
to prior-generation stents in more than 1,600 patients in two parallel trials
at 90 centers worldwide.

Workhorse trial

The pivotal PERSEUS Workhorse trial is evaluating the safety
and efficacy of the TAXUS Element Stent compared to Boston Scientific's
first-generation TAXUS Express Stent in 1,262 patients with de novo lesions.

The prospective, randomized (3:1) trial met its primary
endpoint of non-inferiority for target lesion failure[2] (TLF) at 12 months
with rates of 5.6 percent for the TAXUS Element Stent and 6.1 percent for the
TAXUS Express Stent[3]. The secondary endpoint of in-segment percent diameter
stenosis at nine months as measured by quantitative coronary angiography
(QCA) was also met.

The Workhorse results also demonstrated similar safety for the
TAXUS Element Stent as demonstrated by low rates of Major Adverse Cardiac
Events (MACE) and stent thrombosis. All components of MACE, including cardiac
death, myocardial infarction (MI) and target vessel revascularization (TVR)
were similar to the TAXUS Express Stent control. A numerically lower rate of
non-Q-wave MI for the TAXUS Element Stent resulted in lower overall MI (2.2
vs. 2.9 percent, p=0.48). Stent thrombosis rates using the Academic Research
Coalition (ARC) definite/probable definition were statistically similar for
the TAXUS Element Stent and the TAXUS Express Stent (0.4 and 0.3 percent,
p>0.99).

Small Vessel trial

Results were also presented from the PERSEUS Small Vessel
trial, a single-arm study which compares the TAXUS Element Stent in 224
patients with small vessels (greater than or equal to 2.25 to <2.75 mm in
diameter and less than or equal to 20 mm in length) to a matched historical
control group of 125 patients treated with the Express bare-metal stent. The
trial met its primary endpoint of superiority for in-stent late loss at nine
months with unadjusted values of 0.38 mm for the TAXUS Element Stent and
0.80 mm for the Express Stent (p<0.001). The trial also met its secondary
endpoint of superiority for TLF at 12 months, showing a statistically
significant reduction with an unadjusted rate of 7.3 percent for the TAXUS
Element Stent compared to a pre-specified performance goal of 19.5 percent
(p<0.001) based on historical outcomes for the control stent. The
propensity-adjusted MACE rates were significantly lower for the TAXUS Element
Stent compared to the bare-metal control stent (10.5 vs. 30.4 percent,
p=0.002), showing a safety benefit for the TAXUS Element Stent. Stent
thrombosis rates using the ARC definite/probable definition were comparable
for the TAXUS Element Stent and Express Stent (0.3 vs. 0.6 percent, p=0.65).

"The PERSEUS trials build on the extensive data from the TAXUS
clinical program and extend the consistent outcomes seen in the TAXUS trials
to the novel Element Stent platform," said Louis Cannon, M.D., of the Cardiac
and Vascular Research Center of Northern Michigan in Petoskey, Michigan and
the trial's Co-Principal Investigator. "With the positive outcomes of the
TAXUS Element Stent in workhorse lesions and the superior efficacy data in
small vessels, platinum chromium promises to offer significant advantages in
acute performance with no compromise to safety."

Clinical data from the PERSEUS trials will support regulatory
approval of the TAXUS Element Paclitaxel-Eluting Stent System in Europe, the
U.S. and Japan. The Company is evaluating its PROMUS(R) Element(TM)
Everolimus-Eluting Stent System in the PLATINUM clinical trial, which
completed enrollment of 1,531 patients in September 2009 at 133 sites
worldwide. PLATINUM is a randomized, controlled, pivotal trial designed to
support U.S. and Japanese approval of the PROMUS Element Stent System.
Results are expected to be presented in early 2011.

The Company received CE Mark approval for the PROMUS Element
Stent System in October 2009 and expects CE Mark approval for the TAXUS
Element Stent System in the second quarter of this year. In the U.S., the
Company expects FDA approval for the TAXUS Element Stent System in the middle
of next year and for the PROMUS Element Stent System in the middle of 2012.
In Japan, the Company expects approval for the TAXUS Element Stent System in
late 2011 or early 2012 and for the PROMUS Element Stent System in the middle
of 2012.

The TAXUS Element Stent and the PROMUS Element Stent are
investigational devices in the U.S. and are limited by applicable law to
investigational use only and are not available for sale.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
our product performance, clinical outcomes, regulatory approval of our
products, and our growth strategy. If our underlying assumptions turn out to
be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

———————————

[1] Based on bench testing. Data on file with Boston Scientific.

[2] TLF is defined as ischemia-driven target lesion revascularization
(TLR) or myocardial infarction/cardiac death related to the target vessel.
Complete trial design at Allocco et al., Trials 2010, 11:1.

[3] Bayesian probability of non-inferiority = 99.96 percent.

    CONTACT: Paul Donovan
    +1-508-650-8541 (office)
    +1-508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    +1-508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

CONTACT: Paul Donovan, +1-508-650-8541 (office), +1-508-667-5165 (mobile), Media Relations, Boston Scientific Corporation ; Larry Neumann, +1-508-650-8696 (office), Investor Relations, Boston Scientific Corporation